Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?

Nature Reviews Clinical Oncology, Published online: 23 May 2020; doi:10.1038/s41571-020-0395-xMature results of the PROfound study demonstrate that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib prolongs progression-free survival compared with second-generation hormonal therapies in men with metastatic castration-resistant prostate cancer harbouring BRCA1, BRCA2 or ATM mutations. However, a closer look at the efficacy of olaparib on a gene-by-gene basis suggests that its activity is most pronounced in BRCA2-mutant prostate cancers and might not be equally active in all homologous recombination repair-deficient cancers.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research